Alps Advisors Inc. bought a new position in Cascadian Therapeutics Inc (NASDAQ:CASC) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 56,018 shares of the biopharmaceutical company’s stock, valued at approximately $207,000. Alps Advisors Inc. owned about 0.11% of Cascadian Therapeutics at the end of the most recent quarter.
Other institutional investors have also recently added to or reduced their stakes in the company. SG Americas Securities LLC lifted its stake in shares of Cascadian Therapeutics by 194.7% in the 4th quarter. SG Americas Securities LLC now owns 38,541 shares of the biopharmaceutical company’s stock valued at $143,000 after purchasing an additional 25,464 shares during the period. Dimensional Fund Advisors LP increased its stake in Cascadian Therapeutics by 423.0% in the third quarter. Dimensional Fund Advisors LP now owns 511,899 shares of the biopharmaceutical company’s stock valued at $2,094,000 after purchasing an additional 414,019 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Cascadian Therapeutics by 6,622.8% in the third quarter. JPMorgan Chase & Co. now owns 89,413 shares of the biopharmaceutical company’s stock valued at $367,000 after purchasing an additional 88,083 shares during the last quarter. P.A.W. Capital Corp purchased a new position in shares of Cascadian Therapeutics during the third quarter worth approximately $982,000. Finally, California State Teachers Retirement System purchased a new position in shares of Cascadian Therapeutics during the second quarter worth approximately $226,000. Hedge funds and other institutional investors own 84.67% of the company’s stock.
Cascadian Therapeutics Inc (NASDAQ CASC) traded up $0.02 on Friday, reaching $10.00. The company’s stock had a trading volume of 1,364,200 shares, compared to its average volume of 1,277,753. The stock has a market cap of $505.18, a PE ratio of -7.41 and a beta of 3.96. Cascadian Therapeutics Inc has a 52 week low of $3.18 and a 52 week high of $10.21.
A number of equities analysts have recently issued reports on CASC shares. Zacks Investment Research upgraded shares of Cascadian Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a research report on Monday, November 13th. Raymond James Financial downgraded Cascadian Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 31st. ValuEngine raised Cascadian Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 31st. Finally, BidaskClub raised Cascadian Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, January 31st. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $5.63.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/23/alps-advisors-inc-takes-position-in-cascadian-therapeutics-inc-casc.html.
About Cascadian Therapeutics
Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.
Receive News & Ratings for Cascadian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.